tetano
Editor, Senior Moderator
Vaccine
. 2022 May 27;S0264-410X(22)00641-7.
doi: 10.1016/j.vaccine.2022.05.046. Online ahead of print.
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines
Charlotte Dubé[SUP] 1 [/SUP], Sarah Paris-Robidas[SUP] 1 [/SUP], Guadalupe Andreani[SUP] 1 [/SUP], Cindy Gutzeit[SUP] 2 [/SUP], Marc-André D'Aoust[SUP] 1 [/SUP], Brian J Ward[SUP] 3 [/SUP], Sonia Trépanier[SUP] 4 [/SUP]
Affiliations
Abstract
Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulting in the coronavirus disease 2019 (COVID-19) has afflicted hundreds of millions of people in a worldwide pandemic. Several safe and effective COVID-19 vaccines are now available. However, the rapid emergence of variants and risk of viral escape from vaccine-induced immunity emphasize the need to develop broadly protective vaccines. A recombinant plant-derived virus-like particle vaccine for the ancestral COVID-19 (CoVLP) recently authorized by Canadian Health Authorities and a modified CoVLP.B1351 targeting the B.1.351 variant (both formulated with the adjuvant AS03) were assessed in homologous and heterologous prime-boost regimen in mice. Both strategies induced strong and broadly cross-reactive neutralizing antibody (NAb) responses against several Variants of Concern (VOCs), including B.1.351/Beta, B.1.1.7/Alpha, P.1/Gamma, B.1.617.2/Delta and B.1.1.529/Omicron strains. The neutralizing antibody (NAb) response was robust with both primary vaccination strategies and tended to be higher for almost all VOCs following the heterologous prime-boost regimen.
Keywords: AS03; COVID-19 vaccine; Cross-neutralization; Heterologous regimen; SARS-CoV-2; Variant of concerns; Virus-like particle.
. 2022 May 27;S0264-410X(22)00641-7.
doi: 10.1016/j.vaccine.2022.05.046. Online ahead of print.
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines
Charlotte Dubé[SUP] 1 [/SUP], Sarah Paris-Robidas[SUP] 1 [/SUP], Guadalupe Andreani[SUP] 1 [/SUP], Cindy Gutzeit[SUP] 2 [/SUP], Marc-André D'Aoust[SUP] 1 [/SUP], Brian J Ward[SUP] 3 [/SUP], Sonia Trépanier[SUP] 4 [/SUP]
Affiliations
- PMID: 35654621
- DOI: 10.1016/j.vaccine.2022.05.046
Abstract
Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulting in the coronavirus disease 2019 (COVID-19) has afflicted hundreds of millions of people in a worldwide pandemic. Several safe and effective COVID-19 vaccines are now available. However, the rapid emergence of variants and risk of viral escape from vaccine-induced immunity emphasize the need to develop broadly protective vaccines. A recombinant plant-derived virus-like particle vaccine for the ancestral COVID-19 (CoVLP) recently authorized by Canadian Health Authorities and a modified CoVLP.B1351 targeting the B.1.351 variant (both formulated with the adjuvant AS03) were assessed in homologous and heterologous prime-boost regimen in mice. Both strategies induced strong and broadly cross-reactive neutralizing antibody (NAb) responses against several Variants of Concern (VOCs), including B.1.351/Beta, B.1.1.7/Alpha, P.1/Gamma, B.1.617.2/Delta and B.1.1.529/Omicron strains. The neutralizing antibody (NAb) response was robust with both primary vaccination strategies and tended to be higher for almost all VOCs following the heterologous prime-boost regimen.
Keywords: AS03; COVID-19 vaccine; Cross-neutralization; Heterologous regimen; SARS-CoV-2; Variant of concerns; Virus-like particle.